Compare Aurobindo Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SANOFI INDIA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SANOFI INDIA AUROBINDO PHARMA/
SANOFI INDIA
 
P/E (TTM) x 11.2 38.8 29.0% View Chart
P/BV x 2.1 6.9 30.0% View Chart
Dividend Yield % 0.5 1.3 40.3%  

Financials

 AUROBINDO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
SANOFI INDIA
Dec-18
AUROBINDO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs8306,840 12.1%   
Low Rs5274,630 11.4%   
Sales per share (Unadj.) Rs333.91,203.1 27.8%  
Earnings per share (Unadj.) Rs40.4165.3 24.4%  
Cash flow per share (Unadj.) Rs51.8209.9 24.7%  
Dividends per share (Unadj.) Rs2.5084.00 3.0%  
Dividend yield (eoy) %0.41.5 25.2%  
Book value per share (Unadj.) Rs237.1963.6 24.6%  
Shares outstanding (eoy) m585.9123.03 2,544.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.04.8 42.6%   
Avg P/E ratio x16.834.7 48.5%  
P/CF ratio (eoy) x13.127.3 48.0%  
Price / Book Value ratio x2.96.0 48.1%  
Dividend payout %6.250.8 12.2%   
Avg Mkt Cap Rs m397,569132,078 301.0%   
No. of employees `00017.93.3 540.9%   
Total wages/salary Rs m25,8494,068 635.4%   
Avg. sales/employee Rs Th10,956.98,393.8 130.5%   
Avg. wages/employee Rs Th1,447.71,232.4 117.5%   
Avg. net profit/employee Rs Th1,324.31,153.0 114.9%   
INCOME DATA
Net Sales Rs m195,63627,708 706.1%  
Other income Rs m1,553897 173.2%   
Total revenues Rs m197,18928,605 689.4%   
Gross profit Rs m39,5196,235 633.8%  
Depreciation Rs m6,6801,027 650.4%   
Interest Rs m2,6267 37,514.3%   
Profit before tax Rs m31,7676,098 520.9%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2692,292 317.1%   
Profit after tax Rs m23,6453,806 621.3%  
Gross profit margin %20.222.5 89.8%  
Effective tax rate %22.937.6 60.9%   
Net profit margin %12.113.7 88.0%  
BALANCE SHEET DATA
Current assets Rs m153,64515,922 965.0%   
Current liabilities Rs m120,4296,235 1,931.5%   
Net working cap to sales %17.035.0 48.6%  
Current ratio x1.32.6 50.0%  
Inventory Days Days13564 212.4%  
Debtors Days Days6421 305.2%  
Net fixed assets Rs m103,9097,539 1,378.3%   
Share capital Rs m586230 254.7%   
"Free" reserves Rs m138,32221,962 629.8%   
Net worth Rs m138,90822,192 625.9%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54429,839 886.6%  
Interest coverage x13.1872.1 1.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.9 79.6%   
Return on assets %9.912.8 77.7%  
Return on equity %17.017.2 99.3%  
Return on capital %23.827.5 86.6%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,3167,587 1,282.7%   
Fx outflow Rs m40,5897,145 568.1%   
Net fx Rs m56,727442 12,834.2%   
CASH FLOW
From Operations Rs m16,2203,739 433.8%  
From Investments Rs m-28,768-731 3,935.5%  
From Financial Activity Rs m19,191-1,972 -973.2%  
Net Cashflow Rs m6,6561,036 642.5%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 8.0 14.4 55.2%  
FIIs % 27.7 14.6 189.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 15,184 458.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 205 Points Lower; Power and Realty Stocks Witness Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day on a negative note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 21, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS